Home > Products >

AlbuSorb™ PLUS - Albumin + IgG Depletion Kit From Serum or Plasma

AlbuSorb PLUS


Functional Proteomics
Base Price: $580.00

Product Code: APK285



  • >400 µg total serum protein mass (> 85% Albumin, >85% IgG depleted) from 25 µl serum prep

  • Affinity-type equivalence, virtually no cross-reactivity with other proteins

  • Disposable, no column regeneration or cross-contamination

  • Combines unique bead technology, not based on Blue-dye affinity, with optimized Protein A

  • Mild conditions maintains structural integrity and simple transfer to secondary analysis

  • Suitable for immunoassay, Western blot, 1 & 2D Electrophoresis, enzyme assay, LC-MS

  • Tested species include human, sheep, bovine, rabbit, mouse, rat

  • Validated in the automation compatible high-throughput DPX Technologies XTR tip format

Poly-electrolytes are polymers with repeating units of stationary charges. AlbuSorb™ comes from a class of solid-phase, or surface-based, elastomeric poly-electrolytic surfaces that bind proteins through an empirically derived chemistry combining elements of polymer composition, cross-linking architecture and charge properties. AlbuSorb™ combines with an optimized immobilized Protein A to create AlbuSorb™ PLUS .

Unlike immuno-affinity, the surfaces utilized are disposable eliminating cycle to cycle variance and cross-contamination. AlbuSorb™ PLUS is supplied as a powder. Simply weigh, centrifuge and/or filter, and recover the {albumin + Immunoglobulin} - depleted serum in the supernatant.

Click here to view AlbuSorb™ PLUS Product Sheet

References for AlbuSorbPLUS

Whole blood, serum and plasma samples

DPX Technologies and Biotech Support Group Announce In-Market Partnership for High Throughput Proteomic Sample Prep

Serum/Plasma Samples

Biotech Support Group & Lawson Health Research Institute Enter Collaborative Research Agreement to Monitor Protease Inhibitor Function During Covid-19 Infections

Thangavelu, Bharani, et al. " Dataset of Rat and Human Serum Proteomes Derived from Differential Depletion Strategies prior to Mass Spectrometry. " Data in Brief (2020): 105657.

Application Report

AlbuVoid™ PLUS & AlbuSorb™ PLUS - Evaluating Different Windows of Observation Solves The Many Challenges of Serum Proteomics

AlbuSorb™ Product Extension combines Albumin and Immunoglobulin Depletion in a Consumable Format

References For

Cerebrospinal Fluid
Gwenael Pottiez, Pawel Ciborowski. Proteomic Profiling of Cerebrospinal Fluid Expression Profiling In Neuroscience Neuromethods.2012;64:245-270

Synovial fluid
Happonen KE, Fürst CM, Saxne T et al. PRELP protein inhibits the formation of the complement membrane attack complex.Journal of Biological Chemistry.2012;287(11):8092-100

Zheng H, Soherwardy A, Roy S, Kuruc M, Avadhani S. AlbuVoid™ Enrichment & Antibody Depletion – Tackling the Challenges of Serum Proteomics Part II. Poster reprint first presented at 26th International Molecular Med TRI-CON, March 10-15, 2019, San Francisco, CA USA

Roy, Swapan, and Matthew Kuruc. "Methods to Monitor the Functional Subproteomes of SERPIN Protease Inhibitors." Functional Proteomics. Humana Press, New York, NY, 2019. 41-54.

Dr.Swapan Roy; Amenah Soherwardy; Ravish Amin; Matthew Kuruc Biotech Support Group LLC, Monmouth Junction, NJ - Application Report. AlbuSorb™ Product Extension combines Albumin and Immunoglobulin Depletion in a Consumable Format

Holmberg R, Refai E, Höög A.Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proceedings of the National Academy of Sciences.2011;108(26):10685-9.

Tang MX, Ogawa K, Asamoto M. Effects of Nobiletin on PhIP-Induced Prostate and Colon Carcinogenesis in F344 Rats Nutrition and Cancer.2011;63(2):227-33

Holmberg, Rebecka Apolipoprotein CIII and Ljungan virus in diabetes 2010. Doctoral Thesis

Lu Q, Zheng X, McIntosh T Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Analytical Chemistry.2009;81(21):8715-23

Zubiri, Irene, et al. "Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis." Journal of proteomics 96 (2014): 92-102.

Berggren, Per Olaf, Yang, Shao-Nian. 2012. Methods For Treating And/Or Limiting Development Of Diabetes.U.S. Patent 20120328630 Kind Code: A1, filed June 25, 2012, and issued December 27, 2012.